StreetInsider.com News Articles

IDEAYA's IDE849 shows early survival data in relapsed lung cancer

Fri, 23 Oct 2026 06:00:38 -0400

IDEAYA Biosciences (Nasdaq: IDYA) announced updated Phase 1 clinical results for IDE849 (SHR-4849), an investigational antibody-drug conjugate targeting DLL3, at the European Society for Medical Oncology Congress 2026. The data were presented by partner Jiangsu Hengrui Pharmaceuticals from its China-based Phase 1 study in relapsed small cell lung cancer and neuroendocrine carcinomas.

In second-line SCLC patients (n=51), the study reported a median overall survival of 17.4 months and a median progression-free survival of 6.9 months. The overall response rate in this group was 72.5%, with a confirmed overall response rate of 60.8%. Across all previously treated SCLC patients, including second-line and

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend

Fri, 23 Oct 2026 06:00:00 -0400

17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101)
72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend

Fri, 23 Oct 2026 06:00:00 -0400

17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101)

72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L

IDEAYA shares uveal melanoma trial data from three studies at ESMO

Mon, 19 Oct 2026 06:02:26 -0400

IDEAYA Biosciences (Nasdaq: IDYA) and Servier released clinical data from three ongoing trials evaluating darovasertib in uveal melanoma at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
The OptimUM-01 Phase 2 trial evaluated darovasertib combined with crizotinib in 101 HLA-A*02:01-positive metastatic uveal melanoma patients. Treatment-naïve patients (n=13) showed a median progression-free survival of 7.4 months and median overall survival of 27.1 months. Among 15 patients who had received prior tebentafusp as their only prior systemic therapy, median PFS was 5.7 months and median OS was 12.1 months. The overall response rate across the full population was 22.1%, with

IDEAYA shares uveal melanoma trial data from three studies at ESMO

Mon, 19 Oct 2026 06:02:26 -0400

IDEAYA Biosciences (Nasdaq: IDYA) and Servier released clinical data from three ongoing trials evaluating darovasertib in uveal melanoma at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
The OptimUM-01 Phase 2 trial evaluated darovasertib combined with crizotinib in 101 HLA-A*02:01-positive metastatic uveal melanoma patients. Treatment-naïve patients (n=13) showed a median progression-free survival of 7.4 months and median overall survival of 27.1 months. Among 15 patients who had received prior tebentafusp as their only prior systemic therapy, median PFS was 5.7 months and median OS was 12.1 months. The overall response rate across the full population was 22.1%, with

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou

Mon, 19 Oct 2026 06:00:00 -0400

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy

OptimUM-01 data demonstrates encouraging clinical activity from darovasertib combined with crizotinib in

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou

Mon, 19 Oct 2026 06:00:00 -0400

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or line of therapy

OptimUM-01 data demonstrates encouraging clinical activity from darovasertib combined with crizotinib in

Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens - Ph2 OptiMUM-01 Results Coming Up

Mon, 19 Oct 2026 04:22:40 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $42.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst commented, "We maintain our Market Outperform rating and $42 DCF-derived price target on IDEAYA Biosciences ahead of several key presentations coming at ESMO in Madrid (October 23-27). IDYA will present updated data for lead compound, darovasertib, for both neoadjuvant and metastatic uveal melanoma. Results from the Phase 2 OptiMUM-01 study in HLA-A*02 positive MUM patients (ESMO 2086P) will be critical and could enable NCCN guideline inclusion of darovasertib in this patient population. Partner Hengrui will present updated Phase 1 data for

William Blair Starts Ideaya Biosciences (IDYA) at Outperform

Fri, 16 Oct 2026 02:53:35 -0400

William Blair analyst Alethia Young initiates coverage on Ideaya Biosciences (NASDAQ: IDYA) with a Outperform rating.
The analyst comments: “IDEAYA is a clinical-stage precision oncology company developing medicines that target synthetic lethalities (genetic vulnerabilities) in tumors. The company is nearing its first potential approval for its lead product, darovasertib, in the first half 2027 after strong Phase III data. Our call: We are bullish on an upcoming commercial launch of darovasertib in metastatic uveal melanoma (mUM) and see further potential over time in earlier-stage uveal melanoma patients, where the addressable population is larger. We view its internal R&D capability as unique

William Blair Starts Ideaya Biosciences (IDYA) at Outperform

Fri, 16 Oct 2026 02:53:35 -0400

William Blair analyst Alethia Young initiates coverage on Ideaya Biosciences (NASDAQ: IDYA) with a Outperform rating.
The analyst comments: “IDEAYA is a clinical-stage precision oncology company developing medicines that target synthetic lethalities (genetic vulnerabilities) in tumors. The company is nearing its first potential approval for its lead product, darovasertib, in the first half 2027 after strong Phase III data. Our call: We are bullish on an upcoming commercial launch of darovasertib in metastatic uveal melanoma (mUM) and see further potential over time in earlier-stage uveal melanoma patients, where the addressable population is larger. We view its internal R&D capability as unique

Stifel Starts Ideaya Biosciences (IDYA) at Buy

Tue, 13 Oct 2026 16:07:20 -0400

Stifel analyst Laura Prendergast initiates coverage on Ideaya Biosciences (NASDAQ: IDYA) with a Buy rating and a price target of $48.00.
The analyst comments "We are resuming coverage of IDYA with a Buy rating and $48 target price. IDYA is on the cusp of transitioning to a commercial-stage company in 2027 with darovasertib + crizotinib in 1L metastatic uveal melanoma; the IDYA combo is set to become the new SoC in HLA-A*02:01-negative mUM with HLA-agnostic label upside seeming increasingly likely per recent comments from management. Given the relatively small TAM in 1L mUM, further IDYA upside will depend heavily on darovasertib

Stifel Starts Ideaya Biosciences (IDYA) at Buy

Tue, 13 Oct 2026 16:07:20 -0400

Stifel analyst Laura Prendergast initiates coverage on Ideaya Biosciences (NASDAQ: IDYA) with a Buy rating and a price target of $48.00.
The analyst comments "We are resuming coverage of IDYA with a Buy rating and $48 target price. IDYA is on the cusp of transitioning to a commercial-stage company in 2027 with darovasertib + crizotinib in 1L metastatic uveal melanoma; the IDYA combo is set to become the new SoC in HLA-A*02:01-negative mUM with HLA-agnostic label upside seeming increasingly likely per recent comments from management. Given the relatively small TAM in 1L mUM, further IDYA upside will depend heavily on darovasertib

Form 4 IDEAYA Biosciences, Inc. For: Oct 06 Filed by: Hata Yujiro S

Thu, 08 Oct 2026 19:04:00 -0400
si-local-file:///var/storage/secattach/20261008/27167953.html

Form 144 IDEAYA Biosciences, Inc. Filed by: Hata Yujiro S

Tue, 06 Oct 2026 16:13:00 -0400
si-local-file:///var/storage/secattach/20261006/27155624.html

Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald

Tue, 06 Oct 2026 07:40:44 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ideaya Biosciences (NASDAQ: IDYA).
The analyst commented, "IDEAYA will have meaningful updates for DLL3 ADC IDE849 at ESMO through partner Hengrui and later this year in SCLC/neuroendocrine cancers. The company recently aligned with the FDA on a Ph3 2L+ ESSCLC trial and is positioning IDE849 as potentially best-in-class. The key benchmarks are Zai’s zoci and Amgen’s Imdelltra, particularly in postImdelltra patients. An underappreciated opportunity may be neuroendocrine cancers, where IDE849 could potentially establish a first-in-class position and an expedited path to approval. Together with a clear path forward in ES-SCLC, the

Ideaya Biosciences promotes chief scientific officer to president of R&D

Mon, 28 Sep 2026 06:00:24 -0400

Ideaya Biosciences (NASDAQ: IDYA) announced the promotion of Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

Dr. White has served as Chief Scientific Officer at Ideaya since 2021. Before joining Ideaya, he was Chief Scientific Officer and Head of Tumor Biology at Pfizer, where he led oncology small-molecule research and development efforts. Prior to Pfizer, Dr. White held a position as Professor of Cell Biology at UT Southwestern, where he also served as founding Director of the Cancer Intervention and Prevention Discovery Program during a career spanning more than two decades.

In 2015, Dr.

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

Mon, 28 Sep 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

Mon, 28 Sep 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 25 Sep 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 25 Sep 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA

Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald

Tue, 22 Sep 2026 08:03:58 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ideaya Biosciences (NASDAQ: IDYA).
The analyst commented, "Updated DLL3 ADC, IDE849, data from ~100 patients presented by partner, Hengrui, will be the most important update for IDYA. We should get a first look at data from neuroendocrine carcinomas and landmark OS data in small cell lung cancer (SCLC). In uveal melanoma, we are expecting to see ~100 patients from each of darovasertib's (PKCi) Phase 2 trials in HLA-A2+ metastatic and neoadjuvant patients."
For an analyst ratings summary and ratings history on Ideaya Biosciences click here. For more ratings news on Ideaya

Ideaya Biosciences (IDYA) PT Raised to $57 at Guggenheim

Wed, 09 Sep 2026 07:14:57 -0400
(Updated - September 9, 2026 7:14 AM EDT)
Guggenheim analyst Paul Jeng raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $57.00 (from $54.00) while maintaining a Buy rating.
The analyst commented: "Here, we provide a deep dive overview on the DLL3 landscape and preview upcoming data for IDE849 (DLL3 TOP1i ADC) in 2H26 across two studies in SCLC/NEC, including updated China Phase 1 data at ESMO and initial global Phase 1 data later in the year. Within a deep field of competing ADCs and TCEs, we continue to believe DLL3 is the optimal target for aggressive neuroendocrine neoplasms like ES-SCLC,

Ideaya Biosciences (IDYA) PT Raised to $57 at Guggenheim

Wed, 09 Sep 2026 07:14:57 -0400
(Updated - September 9, 2026 7:14 AM EDT)
Guggenheim analyst Paul Jeng raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $57.00 (from $54.00) while maintaining a Buy rating.
The analyst commented: "Here, we provide a deep dive overview on the DLL3 landscape and preview upcoming data for IDE849 (DLL3 TOP1i ADC) in 2H26 across two studies in SCLC/NEC, including updated China Phase 1 data at ESMO and initial global Phase 1 data later in the year. Within a deep field of competing ADCs and TCEs, we continue to believe DLL3 is the optimal target for aggressive neuroendocrine neoplasms like ES-SCLC,

Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens on IDE849 Advances

Tue, 01 Sep 2026 04:23:46 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $42.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst commented, "IDEAYA's rapid advancement of IDE849 through the clinic is a strong indicator of the company's conviction in the program. This confidence is supported by findings from Hengrui's ongoing Chinese Phase 1 study, as well as emerging experience from IDYA's own open-label, first-in-Western-humans Phase 1 study, for which data are currently undisclosed. While updated efficacy and durability data from Hengrui at ESMO 2026 and the initial Western dataset in 2H26 remain important catalysts, we view the positive FDA interactions, growing clarity

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 06:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 27, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to